Percutaneous intravenous catheter forceps biopsy in right atrial mass: two case reports and literature review

Lei Chang1, Chenyi Gong2, Haitao Lu3, Yihai Liu1, Lina Kang2, Jianzhou Chen2, Lian Wang1,2* and Biao Xu1,2*

Abstract
Background: Primary malignant tumors of the heart are rare. Although preoperative histological diagnosis is difficult, it has paramount value in therapeutic strategy development and prognostic estimation. Herein, we reported 2 cases of intracardiac tumors.

Cases presentation: Both patients presented to the hospital with heart-related symptoms. Echocardiography showed massive masses in the atrium and positron emission tomography–computed tomography (PET/CT) revealed hypermetabolism and invasiveness. One patient cannot take surgery due to extensive metastasis and poor condition. The other patient was primarily diagnosed with lymphoma, and surgery was not recommended. They successfully underwent intravenous atrial biopsy, and histological samples confirmed intimal sarcoma and diffuse large B cell lymphoma. Based on immunohistochemical and molecular assessments, targeted chemotherapy was administered, resulting in clinical and imaging remission at discharge.

Conclusions: Percutaneous intravenous catheter biopsy as a safe invasive test provides an accurate pathological diagnosis after imaging evaluation, and offers a therapeutic direction. Nonmalignant masses and some chemo-radio-sensitive malignant tumors in the atrium could have good prognosis after targeted therapy.

Keywords: Cardiac sarcoma, Intimal sarcoma, Cardiac lymphoma, Intravenous biopsy, Case report

Background
Primary cardiac tumors (PCTs) are extremely rare, with an autopsy incidence ranging from 0.001 to 0.030% [1]. A 14-year population-based study revealed a prevalence for PCT of 1.38/100,000 [2]. A meta-analysis showed that the pooled prevalence of malignancies among patients diagnosed with PCT is 9.9% [3]. Primary cardiac malignancies (PCMs) still have poor prognosis, and attempts to overcome diagnostic and therapeutic difficulties are needed. The majority of PCMs are sarcomas, including angiosarcoma, rhabdomyosarcoma, fibrosarcoma, and Kaposi sarcoma. Mesotheliomas and primary cardiac lymphomas are the next most common primary cardiac malignancies [4]. Intimal sarcoma, a mesenchymal tumor, is the least reported primary cardiac tumor that originates from the tunica intima of large blood vessels, and rarely involves the heart [5]. PCT has multiple clinical presentations, ranging from asymptomatic detection in imaging tests to palpitation, shortness of breath, emaciation and even aborted sudden cardiac death [6]. Preoperative histological diagnosis is difficult but has paramount value in therapeutic strategy development and prognostic estimation. Herein, we successfully performed percutaneous atrial mass biopsy (PAMB), and established histological diagnosis instead of surgery. Safety, procedure and benefit for patients are key points for the extensive use of this invasive diagnostic technique.

*Correspondence: wanglianglyy@163.com; xubiao62@nju.edu.cn
1 Department of Cardiology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Cases presentation

Case 1: A 48-year-old male was presented with palpitation and chest distress after activity for 3 months. Echocardiography revealed a large mass (maximum size: 58 mm × 40 mm) attached to the lateral and posterior atrial walls, invading the inferior vena cava. Cardiac magnetic resonance (CMR) imaging showed right atrial soft tissue mass close to the tricuspid orifice with the valve leaflet (Fig. 1a). Positron emission tomography-computed tomography (PET/CT) suggested enhanced fluorodeoxyglucose (FDG) metabolism signals in the right atrium, pericardium, mediastinum lymph nodes, and left lung nodules (Fig. 1b, c). Surgical resection was not recommended because of extensive metastasis. Totally 2 months later, the patient experienced severe chest tightness, wheezing, sitting breathing, lower limb edema, and bilateral bloody pleural effusion. Radiographic evaluations showed a right atrial mass and multiple metastatic lesions that had progressed (Fig. 2a–d).

To confirm the nature of the mass, PAMB was performed through the femoral vein, wherein three tissues were removed. The pathological analysis revealed thrombus which was consistent with imaging features. We speculated that blood flow changes caused blood turbulence. This could increase the risk of thrombus adhesion on the mass surface and influence biopsy results. After 3 weeks, the patient underwent second PAMB through the internal jugular vein. With the bedside echocardiography auxiliary positioning, three tumor tissues were removed from the atrial mass. The pathological report concluded intraepithelial metaplasia; the abnormal cell pattern showed high-grade spindle cell neoplasm with moderate atypia and focal necrosis, consistent with intimal sarcoma histologically (Fig. 3c, d). The patient was finally diagnosed with primary cardiovascular intimal sarcoma (stage IV).

Subsequently, he underwent exploratory tumor immunotherapy. The primary drug was the immune...
checkpoint inhibitor PD-1 antibody, which could activate endogenous anti-tumor response and has confirmed efficacy in some soft-tissue sarcomas [7]. After five cycles, the patient’s symptoms were relieved, and cardiac function was improved significantly. Re-examination by chest CT revealed a shrunken tumor in the right atrium, and the number of metastases was decreased substantially (Fig. 2e, f). At the time of drafting this manuscript, the condition of patient was stable and receiving the thirteenth cycle of immunotherapy. His health condition and life quality were improved significantly.

Case 2: A 77-year-old woman presented to our hospital with a half-month history of chest tightness and dyspnea. Sinus tachycardia and pulmonary moist rales were found on physical examination. Trans-thoracic echocardiography revealed an intracardiac mass (maximum size: 49 mm × 38 mm) attached to the left atrium that invaded the right atrial walls and tricuspid annulus. The atrial mass protruding into the pericardial cavity caused moderate pericardial effusion and early signs of tamponade. CMR confirmed the presence of an invasive intracardiac mass (Fig. 4a, b) and PET-CT scan revealed high FDG uptake in the neoplasm and mediastinum lymph nodes (Fig. 4c). The patient underwent pericardium puncture drainage, and abnormal lymphocytes were found by pericardial effusion smear examination. Abnormally increased percent of heteromorphic monoclonal B lymphocytes was detected by flow cytometry. Given the right atrium invasion of the mass, and our successful experience of PAMB in the right atrium, we performed percutaneous jugular puncture and catheterization, and subsequent atrium angiography revealed a filling defect in the right atrium. Then, biopsy catheter was positioned at the neoplasm, and TTE provided multiple heart sections that confirmed the relative positions of biopsy forceps, atrial walls, and the mass. We successfully obtained 2 tissue pieces to avoid thoracotomy, without complication.

Immunohistochemical analysis of the specimen showed that the obtained tumor cells were positive for CD20, MUM1, CD5, and Bcl-2; negative for CD3, CD99, CD10 and CD30; and equivocal for Bcl-6. Ki67, Bcl-2, and c-MYC labeling indexes were all 90%
However, bone marrow biopsy showed no infiltration of abnormal lymphocytes. Then, the patient was diagnosed with cardiac diffuse large B cell lymphoma, of non-germinal center B-cell-like type. After 3 cycles of chemotherapy with R-miniCHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone), the clinical symptoms were improved remarkably. Repeated echocardiography demonstrated disappearance of the intracardiac mass. PET/CT showed no area of FDG hypermetabolism in the heart or intrathoracic lymph nodes. The patient would accept the full course of treatment with continuous follow-up.

**Discussion and conclusions**

A recent multicenter analysis showed that PCM mainly affected adults (mean age of 53 years), and had a dismal long-term survival rate despite various modes of treatment [8]. The overall 1-year and 5-year survival rates were 45.3% and 11.5% in the latter study. Patients who underwent surgery had significantly better survival compared with those administered the non-surgical treatment. Moeri-Schimmel et al. indicated that most PCM patients who received postoperative radiotherapy had longer survival time than those who undergo only surgery [9]. Multi-institutional data from the National Cancer Database also confirmed that stage III PCM patients who undergo surgery and receive perioperative chemotherapy have better survival compared with those who did not receive this treatment [8]. Although surgical resection remains the first treatment choice for cardiac sarcoma [1], radiotherapy and chemotherapy are increasingly important. Thus, individualized radiotherapy and chemotherapy should be recommended in inoperable patients. A prospective study of right-sided tumors showed that neoadjuvant chemotherapy reduces the tumor burden, improving resectability and survival in complex cardiac tumors [10].

Although intracardiac mass is considered as a dangerous signal of PCM, it should be noticed that a neoplasm located in the atrium usually causes less
systolic dysfunction and ventricular arrhythmia. Moreover, benign lesions such as thrombus and myxoma, accounting for a large proportion of atrial masses, but seldom appear in ventricles. Therefore, the criticality of atrial mass is different from that of ventricular mass. For atrial mass, more effort is needed to enable precise diagnosis, especially histological diagnosis. Echocardiography, CT, CMR, and PET/CT imaging could help in the preliminary differentiation between malignant and benign tumors based on tumor shape, aggressiveness, and radioactive material intake [11, 12]. However, several intra-atrial PCMs firstly misdiagnosed as benign tumors or incompletely resected may relapse in a short time [13]. Generally, histological diagnosis before tumor therapy could avoid this situation and help differentiate primary sarcomas from other malignancies (such as lymphomas that do not require surgery). After that, the patients could be administered the best-personalized multimodality treatment [14]. In patients with potential resectable cardiac sarcomas but limited by poor cardiac and pulmonary functions [15], pathological results could facilitate neoadjuvant chemotherapy to improve the basic condition of patients and create opportunities or strengthen the effect of surgical resection.

The endomyocardial biopsy technology has been widely used in cardiomyopathy, and has been extended to ventricle mass biopsy. By contrast, atrial biopsy has not been promoted for some reason. Atrial biopsy means thinner cardiac muscle walls, closer intervention to the relatively fragile vein, and higher risk of thrombus detachment. In 1989, Gosalakkal and Sugrue [16] firstly reported atrium biopsy and removed the tumor tissue from the cardiac chamber. To further evaluate the safety and efficacy of percutaneous atrial mass biopsy, we analyzed 51 cases in 47 articles and our 2 PAMB cases (Table 1). Most patients had undergone simple right atrial lump biopsy, while 3 cases underwent transseptal left atrial biopsy. Of all cases, only 1 patient reported potential complications post-biopsy [17]. The latter patient developed severe hypotensive shock after the procedure. After fluid resuscitation and treatment with vasoactive agents, the shock symptoms were stabilized. Since no obvious signs of perforation and rupture of the atrium or inferior vena cava were noted, mechanical damage to the heart caused by biopsy was not considered.

Among 37 cases with reported malignant tumors, lymphomas accounted for the largest proportion (15/37), followed by soft tissue sarcomas (13/37), and 9/37 reported metastatic tumors. Table 2 shows their prognoses differed from mass location and pathological results. In all patients, atrial lymphoma patients had the best prognosis, including 11 patients who presented clinical remission or even cured after receiving corresponding chemotherapy; the prognoses of another 4 lymphoma patients were not reported. Most atrial soft-tissue sarcoma patients cannot tolerate surgery and radiotherapy due to heart-related symptoms; 6 patients achieved clinical remission and 3 had tumor exacerbation in short-term visits. Of another 4 patients diagnosed with atrial thrombosis, 2 had satisfactory prognosis, and 1 diagnosed with angiosarcoma by subsequent surgical specimens died of tumor recurrence and metastasis [34]. In addition, a patient pathologically diagnosed with an IgG4-related disease received hormone therapy and showed good prognosis [61].

For various spatial atrial mass locations, different vessel approaches and ultrasonic guidance methods could be selected in PAMB. Biopsy has been performed via the internal jugular, femoral and subclavian veins. Transesophageal echocardiography (TEE) is highly effective in mass locating and biop Tome guidance. Hence, about 50% of physicians use TEE as a supplementary tool to digital subtraction angiography (DSA). Transthoracic echocardiography (TTE) is more convenient but provides less location information compared with TEE, thereby necessitating highly experienced doctors. Intracardiac echocardiography (ICE) can provide the most precise intra-atrial imaging and structures, but requires an extra-intravenous ultrasound catheter, which limits its application; only about 33% of physicians utilize this method. Table 3 shows the proportion of different guiding methods in all trans venous atrium biopsy cases.

Percutaneous intravenous catheter biopsy provided accurate pathological diagnosis after imaging evaluation, avoiding unnecessary surgical excision and reducing medical resource waste. Benign tumors, thrombus, bacterial vegetation, and lymphoma detected by PAMB could be cured. Nevertheless, when pathological biopsy results suggest thrombus but do not correspond to clinical symptoms, doctors should consider the possibility of false negatives. Multiple biopsies from different vessel approaches and varied mass locations might reduce the probability of misleading results. However, whether biopsies are beneficial to PCM patients is currently controversial. Ryo et al. [34] speculated that intravenous cardiac biopsy and subsequent chemotherapy is not beneficial to cardiac sarcoma patients. The core challenge is the effectiveness of subsequent anti-tumor therapy. Significantly, with the development of anti-tumor therapy, appropriate treatments have proved effective. PAMB as a safe, effective, and minimally invasive procedure for histological diagnosis before surgical resection would be applied increased comprehensively.
| Age | Sex | Biopsy location | Transvenous pathway | Guidance Method | Presenting reasons | Pathological diagnosis | Treatment | Outcome | PMID       |
|-----|-----|-----------------|---------------------|-----------------|-------------------|-----------------------|-----------|---------|------------|
| 14  | Male| RA              | Femoral vein        | DSA + TEE       | Chest pain, cough, and hemoptysis | /                     | /         | /       | 2,334,836 [18] |
| 46  | Female| RA            | Jugular vein        | DSA             | Symptoms of Upper respiratory infection | Metastases of melanoma | /         | /       | 2,765,329 [16] |
| 83  | Female| RA             | Femoral vein        | DSA             | Dyspnea and hypodynamia | Papillary fibroelastoma | Symptomatic treatment | /       | 2,816,690 [19] |
| 69  | Female| RA             | Femoral vein        | DSA + TEE       | Dyspnea, edema, and syncope | Thrombus | Surgical resection | Remission | 7,499,910 [20] |
| 52  | Female| RA             | Femoral vein        | DSA + TEE       | History of cirrhosis | Metastases of liver cancer | /         | Deceased | 8,131,572 [21] |
| 69  | Male  | RA             | Femoral vein        | DSA + TEE       | Dyspnea, cough, and hemoptysis | Metastases of melanoma | /         | 8,154,436 [22] |
| 69  | Female| RA             | Jugular vein        | DSA + TEE       | Dyspnea, dehydration, and ventricular tachycardia | Thrombus | Symptomatic treatment | /       | 8,365,328 [23] |
| 62  | Male  | RA             | Jugular vein        | DSA + TEE       | Edema and hepatic encephalopathy | Metastatic adenocarcinoma | /         | Deceased | 8,498,328 [24] |
| 73  | Female| RA             | Jugular vein        | DSA + TEE       | Edema, cough, fever, and dyspnea | Lymphoma | Chemotherapy | Remission | 8,579,042 [25] |
| 69  | Male  | RA             | Femoral vein        | DSA + ICE       | Flu symptoms | Metastasis of lung cancer | /         | 8,611,294 [26] |
| 73  | Male  | RA             | Jugular vein        | DSA + TEE       | Asymptomatic | Metastases of melanoma | Chemotherapy | /         | 8,945,488 [27] |
| 35  | Male  | RA             | Femoral vein        | DSA + TEE       | Dyspnea and cough | Angiosarcoma | Chemotherapy | Remission | 8,974,823 [28] |
| /   | /     | RA             | Jugular vein        | DSA + TEE       | / | Angiosarcoma | / | 9,070,559 [29] |
| 62  | Male  | RA             | Jugular vein        | DSA + TEE       | Dyspnea, chest pain and dyspnea | Undifferentiated sarcoma | Chemotherapy | Deceased | 9,339,428 [30] |
| 66  | /     | RA + AS        | Femoral vein        | DSA + TEE       | Myocardial infarction | Lymphoma | Chemotherapy | / | 9,454,452 [31] |
| 64  | Female| RA             | /                   | DSA + TEE       | Dizziness | Lymphoma | / | 9,487,479 [32] |
| 47  | Male  | RA             | Jugular vein        | DSA + TTE       | Dyspnea, edema and pleural effusion | Lymphoma | Chemotherapy | / | 9,829,904 [33] |
| 50  | Male  | RA             | /                   | DSA + TEE       | Orthopnea, fever, and pleural effusion | Thrombus | Surgical resection | Deceased | 9,932,633 [34] |
| 39  | Female| /              | /                   | /               | / | Myxoma | / | 10,231,677 [35] |
| /   | /     | RA             | /                   | /               | / | / | / | 10,763,354 [36] |
| 77  | Female| RA             | /                   | DSA + TEE       | Dyspnea, edema and hypodynamia | Lymphoma | Chemoradiotherapy | Remission | 10,790,358 [37] |
| 75  | Male  | RA             | Femoral vein        | DSA + TEE       | Hemoptysis | Lymphoma | Chemotherapy | Remission | 10,842,397 [38] |
| 79  | Female| RA             | Femoral vein        | DSA + ICE       | Dyaspnea and edema | Neuroblastoma | / | 10,952,166 [39] |
| /   | /     | LA             | /                   | DSA + TEE       | / | Atrial sarcoma | / | 11,223,492 [40] |
| 52  | Male  | RA             | Jugular vein        | DSA + TEE       | Epigastric ache | Angiosarcoma | Chemotherapy | Remission | 12,019,433 [41] |
| 62  | Male  | RA             | Femoral vein        | DSA + TEE       | Dyspnea and dizziness | Lymphoma | Chemotherapy | Remission | 12,848,708 [42] |
| Age | Sex | Biopsy location | Transvenous pathway | Guidance Method | Presenting reasons | Pathological diagnosis | Treatment | Outcome | PMID |
|-----|-----|-----------------|---------------------|----------------|-------------------|-----------------------|-----------|---------|------|
| 64  | Male | RA              | Jugular vein        | DSA + TEE      | Heart failure     | Lymphoma              | Chemotherapy | Remission | 14,622,547 [43] |
| 52  | Male | RA              | Jugular vein        | DSA + TEE      | Dyspnea, chest pain, and edema | Metastases of liver cancer | Symptomatic treatment | Deceased | 15,546,373 [44] |
| 63  | Female | RA             | Jugular vein        | DSA + ICE     | Dyspnea and centrum fracture | Lipomyoma | Expectant treatment | / | 16,880,106 [45] |
| 61  | Male | RA              | Subclavian vein for biopsy, femoral vein for ICE | DSA + ICE     | Ventricular tachycardia | Lymphoma | / | / | 17,015,040 [46] |
| 38  | Male | RA              | /                   | DSA + TTE      | Dyspnea          | Lymphoma              | Chemotherapy | Remission | 17,383,751 [47] |
| 52  | Male | RA              | Femoral vein        | DSA + ICE     | Cardiac tamponade | Granulocytic sarcoma | Chemoradiotherapy and hematopoietic stem cell transplantation | Remission | 18,498,027 [48] |
| 56  | Female | /              | /                   | /              | Repeated peri-cardial effusion | / | / | / | 18,805,775 [49] |
| 67  | Female | RA             | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE     | The discomfort of the precordial area | Paragangliomas | Surgical resection | / | 18,818,096 [17] |
| 47  | Female | RA             | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE     | Hypodynamia and atrial fibrillation | Paragangliomas | Surgical resection | / | 18,818,096 [17] |
| 30  | Male | RA/IVC          | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE     | Polyserositis and edema after heart transplant | Bacterial emboli | Surgical resection | Remission | 18,818,096 [17] |
| 70  | Male | RA/IVC          | /                   | /              | Ascites after heart transplantation | Cardiac amyloidosis | Symptomatic treatment | Deceased | 18,818,096 [17] |
| 63  | Female | RA             | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE     | Chest discomfo rt and edema | Lymphoma | Chemotherapy | Remission | 19,057,087 [50] |
| 59  | Male | RA              | /                   | DSA + TEE      | Dyspnea, cough, chest discomfort, fever and hypodynamia | / | | | |
| 64  | Female | RA             | /                   | DSA + TTE      | Dizziness and history of endometrial adenocarcinoma | Metastases of endometrial adenocarcinoma | / | | 20,027,104 [52] |
| 22  | Female | RA             | /                   | DSA + ICE      | Dyspnea and syncope | Angiosarcoma | Chemotherapy | / | 20,585,357 [53] |
| 57  | Female | RA              | /                   | DSA + TEE      | Dyspnea and back pain | Intimal sarcoma | Chemotherapy | Remission | 20,966,612 [54] |
| 44  | Male | RA              | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE     | Dyspnea | Lymphoma | Chemotherapy | Remission | 22,576,384 [55] |
| 31  | Male | LA              | /                   | DSA + TEE      | Dyspnea and hypodynamia | Poorly differentiated sarcoma | Chemotherapy | Deceased | 23,109,774 [56] |
| 46  | Male | RA              | Femoral vein        | DSA + ICE     | History of myxoma | Myxoma | Expectant treatment | Remission | 25,240,574 [57] |
| 53  | Male | RA              | Right femoral vein for biopsy, left femoral vein for ICE | DSA + ICE     | Dyspnea and weight loss | Metastases of lung cancer | Chemotherapy | Deceased | 25,810,740 [58] |
### Table 1 (continued)

| Age | Sex  | Biopsy location | Transvenous pathway | Guidance Method | Presenting reasons                                      | Pathological diagnosis          | Treatment       | Outcome       | PMID          |
|-----|------|-----------------|---------------------|-----------------|---------------------------------------------------------|-------------------------------|----------------|---------------|---------------|
| 51  | Female | RA              | /                   | DSA + ICE       | Dyspnea and edema                                        | Angiosarcoma                 | Chemotherapy    | Deceased      | 25,810,740    |
| 47  | Female | RA              | Femoral vein        | DSA + ICE       | Neoadjuvant chemotherapy for breast cancer                | Thrombus                     | Surgical resection | Remission      | 27,068,834    |
| 59  | Male   | LA              | /                   | DSA + TEE       | Fever, weight loss, and history of HIV infection          | Lymphoma                     | Chemotherapy    | Remission      | 31,020,117    |
| 61  | Male   | RA              | /                   | DSA + ICE       | Jaundice, hypodynamia and diagnosed as IgG4-related disease | IgG4-related disease         | Hormonotherapy  | Remission      | 31,118,383    |
| 47  | Female | RA              | Jugular vein for biopsy, femoral vein for ICE | DSA + ICE       | Cough and pulmonary nodules                              | Angiosarcoma                 | Chemotherapy    | Remission      | 32,874,873    |
| 48  | Male   | RA              | Femoral vein and jugular vein | DSA + TTE       | Palpitation and chest discomfort                          | Intimal sarcoma               | Chemotherapy    | Remission      | Present case  |
| 77  | Female | RA              | Jugular vein        | DSA + TTE       | Dyspnea and chest discomfort                              | Lymphoma                     | Chemotherapy    | Remission      | Present case  |

### Table 2  Prognosis of patients differs with respect to the mass locations and the pathological results

| Neoplasm location and pathology | Overall response | Progressive disease | Not mentioned | Total |
|---------------------------------|------------------|----------------------|---------------|-------|
| All cases                       | 22               | 9                    | 22            | 53    |
| **First attack symptom**        |                  |                      |               |       |
| Related to the mass             | 17               | 8                    | 13            | 38    |
| Unrelated to the mass           | 5                | 1                    | 4             | 10    |
| No discomfort or not mentioned  | 0                | 0                    | 5             | 5     |
| **Biopsy location**             |                  |                      |               |       |
| Right atrium or atrial septum   | 21               | 8                    | 21            | 50    |
| Involved left atrium             | 1                | 1                    | 1             | 3     |
| **Malignant tumor**             |                  |                      |               |       |
| Lymphoma                        | 11               | 0                    | 4             | 15    |
| Metastatic tumor                 | 0                | 4                    | 5             | 9     |
| Soft-tissue sarcoma             | 6                | 3                    | 4             | 13    |
| **Benign tumor**                |                  |                      |               |       |
| Lipomyma                        | 0                | 0                    | 1             | 1     |
| Myxoma                          | 1                | 0                    | 1             | 2     |
| Paraganglioma                   | 0                | 0                    | 2             | 2     |
| Fibroma                         | 0                | 0                    | 1             | 1     |
| **Others**                      |                  |                      |               |       |
| Thrombus                        | 2                | 1                    | 1             | 4     |
| Bacterial vegetation            | 1                | 0                    | 0             | 1     |
| IgG4-related diseases           | 1                | 0                    | 0             | 1     |
| Myocardial amyloidosis          | 0                | 1                    | 0             | 1     |
| Not mentioned                   | 0                | 0                    | 3             | 3     |

The overall response means patients' clinical symptoms were relieved and/or healed, or the tumor volume was reduced. Progressive disease means patients could not benefit from the treatment, it was worsened, or led to death.
The information and data of the 2 patients were acquired from the Hospital information system. The literature review datasets analyzed in the current study are not publicly available due to the protection of individual privacy. The literature review datasets analyzed in the current study are not publicly available due to the protection of individual privacy. Informed consent was obtained from the patients for the publication of this report and any accompanying images. A copy of the written consent is available for review at any time.

The study was approved by the Medical Ethics Committee of Nanjing Drum Tower Hospital. Competing interests: The authors declare that they have no competing interests. Funding: This study was supported by grants from the Natural Science Foundation of China (81870204), and Medical Science and technology development Foundation, Nanjing Department of Health (2XX19017). No funding body participated in the design of the study and the collection, analysis, and interpretation of data and the writing the manuscript.

### Abbreviations

- PCT: Primary cardiac tumor
- PCM: Primary cardiac malignancy
- PET/CT: Positron emission tomography-computed tomography
- CMR: Cardiac magnetic resonance
- FDG: Fluorodeoxyglucose
- PAMH: Percutaneous atrial mass biopsy
- TEE: Transesophageal echocardiography
- ICE: Intracardiac echocardiography
- DSA: Digital subtraction angiography

### Authors’ contributions

LC: data review and manuscript writing. CYG: data collection and manuscript writing. HTL: data collection and management. LNK: manuscript revision and data review. JZC: data review and manuscript review. LW and BX: biopsy and study design. All authors have read and approved the final manuscript.

### Availability of data and materials

The information and data of the 2 patients were acquired from the Hospital Information System are not publicly available due to the protection of individual privacy. The literature review datasets analyzed in the current study are not publicly available due to the protection of individual privacy. Informed consent was obtained from the patients for the publication of this report and any accompanying images. A copy of the written consent is available for review at any time.

### Declarations

**Ethics approval and consent to participate**
The study was approved by the Medical Ethics Committee of Nanjing Drum Tower Hospital, Medical School of Nanjing University (2019-190-01). Written informed consent was obtained from the patients for the publication of this report and any accompanying images. A copy of the written consent is available for review at any time.

**Consent for publication**
All authors declared that the patient has signed written informed consent for publication of clinical, radiological, and biological data.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1. Department of Cardiology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China. 2. Department of Cardiology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, Jiangsu, China. 3. Department of Cardiology, Anhui Sixian Peoples Hospital, Suzhou 234300, Anhui, China.

### Table 3 Proportion of different guiding methods in all transvenous atrium biopsy cases

| Reported imaging and guidance method   | Not mentioned |
|----------------------------------------|---------------|
| DSA only                               |               |
| TEE + DSA                              |               |
| TEE + ICE                              |               |
| ICE + DSA                              |               |
| Number of cases                        | 2             |
| Proportion                             | 4.1%          |
|                                       | 12.2%         |
|                                       | 49.0%         |
|                                       | 34.7%         |

**References**

1. Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours: diagnosis and management. Lancet Oncol. 2005;6(4):219–28.
2. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, Guerini F, Catapi E, Focardi M, Severi S. Incidence rate of primary cardiac tumors: a 14-year population study. J Cardiovasc Med (Hagerstown) 2016;17(1):37–43.
3. He S, Cao Y, Qin W, Chen W, Yin L, Chai H, Tao Z, Tang S, Qiu Z, Chen X. Prevalence of primary cardiac tumor malignancies in retrospective studies over six decades: a systematic review and meta-analysis. Oncotarget. 2017;8(26):43284–94.
4. Arazo PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. Radiographics. 1999;19(6):1421–34.
5. Ibrahim A, Luk A, Singhal P, Wan B, Zavodni A, Cusimano RJ, Butany J. Primary atrial (spindle cell) sarcoma of the heart: a case report and review of the literature. Case Rep Med. 2013;2013:461815.
6. Poterucha TJ, Kochav J, O’Connor DS, Rosner GF. Cardiac tumors: clinical presentation, diagnosis, and management. Curr Treat Options Oncol. 2019;20(8):66.
7. Italano A, Beller A, D’Angelo S. PDI/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. J Hematol Oncol. 2020;13(1):55.
8. Sultan I, Bianco V, Haberthuer A, Kilk A, Gleason TG, Aranda-Michel E, Harinstein ME, Martinez-Meehan D, Arnaoutakis G, Okusanya O. Long-term outcomes of primary cardiac malignancies: multi-institutional results from the national cancer database. J Am Coll Cardiol. 2020;75(18):2338–47.
9. Moeri-Schimmel R, Pras E, Desar I, Krol S, Braam P. Primary sarcoma of the heart: case report and literature review. J Cardiothorac Surg. 2020;15(1):104.
10. Abu SW, Ramlawi B, Shapira OM, Al JO, Ravi V, Benjamin R, Durand JB, Leja MJ, Blackmon SH, Bruckner BA, Reardon MJ. Improved outcomes with the evolution of a neoadjuvant chemotherapy approach to right heart sarcoma. Ann Thorac Surg. 2017;104(1):90–6.
11. Lestuzzi C, De Paoli A, Barresi T, Micol G, Buonadonna A. Malignant cardiac tumors: diagnosis and treatment. Future Cardiol. 2015;11(4):485–500.
12. Kassi M, Polsani V, Schutt RC, Wong S, Nabi F, Reardon MJ, Shah DJ. Differentiating benign from malignant cardiac tumors with cardiac magnetic resonance imaging. J Thorac Cardiovasc Surg. 2019;157(5):1912–22.
13. Lestuzzi C. Primary tumors of the heart. Curr Opin Cardiol. 2016;31(6):593–8.
14. Lestuzzi C, Reardon MJ. Primary cardiac malignancies: the need for a multidisciplinary approach and the role of the cardio-oncologist. J Am Coll Cardiol. 2020;75(18):2348–51.
15. Blackmon SH, Patel A, Reardon MJ. Management of primary cardiac sarcomas. Expert Rev Cardiovasc Ther. 2008;6(9):1217–22.
16. Gosalakkal JA, Sugrue DD. Malignant melanoma of the right atrium: ante-mortem diagnosis by transvenous biopsy. Br Heart J. 1989;62(2):159–60.
17. Sze DY, Lee DF, Hofmann LV, Petersen E. Biopsy of cardiac masses using a stabilized intracardiac echocardiography-guided system. J Vasc Interv Radiol. 2008;19(11):1662–7.
18. Scott PJ, Ettles DF, Rees MR, Williams GJ. The use of combined transoesophageal echocardiography and fluoroscopy in the biopsy of a right atrial mass. Br J Radiol. 1990;63(747):222–4.
19. Schrønder ME, Katz E, Rotterdam H, Slater J, Weiss EC, Korzonen I. Right atrial papillary fibroelastoma: diagnosis by transesophageal and transesophageal echocardiography and percutaneous transvenous biopsy. Am Heart J. 1989;118(5 Pt 1):1047–50.
20. Chirillo F, Risica G, Stritton P. Mobile right atrial mass biopsy guided by biplane transesophageal echocardiography. Int J Card Imaging. 1995;11(3):201–3.
21. Van Camp G, Abdulsater J, Cosyns B, Liebens I, Vandeven, J. Transesophageal echocardiography of right atrial metastases of a hepatocellular carcinoma. Chest. 1994;105(3):945–7.
22. Rubin DC, Ziskind AA, Hawke MW, Plotnick GD. Transesophageal echocardiographically guided percutaneous biopsy of a right atrial cardiac mass. Am Heart J. 1994;127(4Pt 1):935–6.
23. Starr SK, Pugh DM, O’Brien-Ladner A, Sittes S, Wilson DB. Right atrial mass biopsy guided by transesophageal echocardiography. Chest. 1993;104(3):969–70.
24. Salka S, Siegel R, Sagar KB. Transvenous biopsy of intracardiac tumor under transesophageal echocardiographic guidance. Am Heart J. 1993;125(6):1782–4.
25. Azuma T, Ohira A, Akagi H, Yamamoto T, Tanaka T. Transvenous biopsy of a right atrial tumor under transesophageal echocardiographic guidance. Am Heart J. 1996;131(2):402–4.
26. Segar DS, Bourdillon PD, Elsner G, Kesler K, Feigenbaum H. Intracardiac biopsy of a right atrial tumor: guided by transesophageal echocardiography. Cathet Cardiovasc Diagn. 1995;36(3):297–9.
27. Malouf JF, Thompson RC, Maples WJ, Wolfe JT. Diagnosis of right atrial metastatic melanoma by transesophageal echocardiographically guided transvenous biopsy. Mayo Clin Proc. 1996;71(12):1167–70.
28. Hammadouche AJ, Chaaban F, Watson RM, Milliman A. Transesophageal echocardiography-guided transvenous endomyocardial biopsy used to diagnose primary cardiac angiosarcoma. Cathet Cardiovasc Diagn. 1996;37(3):347–9.
29. Lynch M, Clements SD, Shanevisse JS, Chen CC, Martin RP. Right-sided cardiac tumors detected by transesophageal echocardiography and its usefulness in differentiating the benign from the malignant ones. Am J Cardiol. 1997;79(6):781–4.
30. Savoca MT, Liguori C, Nahar T, Marboe C, Weinberger J, Di Tullio MR, Nahor T, Mavelek B, Xenics P. Diagnosis of a heart tumor by transesophageal echocardiography-guided biopsy of a right atrial mass. J Am Soc Echocardiogr. 1997;10(7):752–5.
31. Fischer JL, Antonic D, Quadbeck J, Kramer H, Tiefenbock G, Aschenbrenner G, Strohm H, Krieg HJ, Fuchs C, Gross S, Schlemmer M, Nibler K, Garbrecht M, Henselmann L, Bultmann B. High malignant B-cell non-Hodgkin lymphoma of the heart: a case of primary cardiac angiosarcoma. Z Kardiol. 1997;86(10):848–56.
32. Nitta R, Sakomura Y, Tanimoto K, Hidai T, Kasanuki H, Aomi S, Nishikawa G, Strohm H, Krieg HJ, Fuchs C, Gross S, Schlemmer M, Nibler K, Garbrecht M, Henselmann L, Bultmann B. High malignant B-cell non-Hodgkin lymphoma of the heart: a case of primary cardiac angiosarcoma. Jpn Circ J. 2000;64(8):638–40.
33. Aqel R, Dobbs J, Laub Y, Lloyd S, Gupta H, Zoghbi GJ. Transvenous biopsy of a right atrial mass under intracardiac echocardiographic guidance. J Am Soc Echocardiogr. 2000;19(8):1072–5.
34. Mitchell JR, Jenner M. Right atrial angiosarcoma: diagnosis by intracardiac echocardiographic-guided biopsy of a primary cardiac tumor. Eur J Echocardiogr. 2007;8(6):505–6.
35. Abramowtiz Y, Hiller N, Perlman G, Adamon D, Beeri R, Chajek-Shaul T, Leibowitz D. The diagnosis of primary cardiac lymphoma by right heart catheterization and biopsy using fluoroscopic and transthoracic echocardiographic guidance. Int J Cardiol. 2007;118(2):e39–40.
36. Kozelj M, Zorman D, Mrevlje B, Zver S. Cardiac granulocytic sarcoma diagnosed by intracardiac echocardiography-guided biopsy. Int J Hematol. 2008;88(1):101–3.
37. Kutiya V, Merkely B, Pozsonyi Z, Hosszu K, Szilagyi S, Balazs G, Toth A, Popp M, Geller L. Intracardiac echocardiography-guided cardiac mass biopsy. Echocardiography. 2008;25(3):273–7.
38. Higo T, Takemoto M, Ogawa K, Iinoe S, Eshima K, Tada H, Sunagawa K. Intracardiac echocardiography-guided cardiac tumor biopsy. Cardiology. 2009;73(2):381–3.
39. Brueck M, Benderski D, Stahl U, Kramer W. Superior vena cava syndrome by cardiac tumor. Med Klin (Munich). 2009;104(1):52–7.
40. Kanwali K, Mort AJ, Transthoracic echocardiography-guided biopsy of a metastatic endometrial adenocarcinoma in the right atrium: a review of diagnosis and treatment of cardiac masses. Am J Ther. 2010;17(4):e118–25.
41. Kuppahally SS, Litwin SE, Michaels AD. Endomyocardial biopsy of right atrial angiosarcoma guided by intracardiac echocardiography. Cardiol Res Pract. 2010;2010:681726.
42. Hosokawa Y, Kodani E, Yasuma Y, Kamiya M, Yohshika M, Hirasa Y, Nakagomi A, Atsahashi H, Maeda S, Mizuno K. Cardiac angiosarcoma diagnosed by transvenous endomyocardial biopsy with the aid of transesophageal echocardiography and intra-procedural consultation. Int J Heart J. 2010;51(5):367–9.
43. Kamiya K, Sakakibara M, Yamada S, Tan M, Furuhashi T, Kutsuji H. Diffuse large B-cell lymphoma diagnosed by intracardiac echocardiography-guided cardiac tumor biopsy. Int J Cardiol. 2011;151(1):1043–7.
44. Satya K, Kalige G, Navarijo J, Raskh A, Wilson JM. Transseptal biopsy of a left atrial mass with 3-dimensional transesophageal echocardiographic guidance. Tex Heart Inst J. 2012;39(5):707–10.
45. Konecny T, Reeder G, Noseworthy PA, Konecny D, Carney JA. Rare cardiac human herpesvirus-8 positive B-cell lymphoma manifesting as an atrial tumor. A case report and review of the literature. Heart Lung. 2012;41(4):e118–25.
46. Park KI, Kim MJ, Oh JK, Lee JH, Park JH, Choi SW, Jeong JO, Seong IW. Intracardiac echocardiography to guide myocardial biopsy of a primary cardiac tumor. Korean Circ J. 2013;43(5):165–8.
47. Azzolin L, de Hemptinne Q, Asgar A, Ibrahim R. Right atrial mass in a patient with breast cancer: percutaneous transcatheter biopsy under intracardiac echocardiography-guidance. BMJ Case Rep. 2016;2016:1136.
48. Schneider CM, Buatti J, Schwamborn K, Dirschinger R. Diagnosis of a rare cardiac human herpesvirus-8 positive B-cell lymphoma manifestation: a case report of a transesophageal echocardiography-guided trans-septal catheter biopsy. Echocardiography. 2018;2018(22):e37.
49. Maeda R, Naito D, Adachi A, Shiraishi H, Sakamoto T, Matoba S. IgG4-related disease involving the cardiovascular system: an intracardiac mass and a mass lesion surrounding a coronary artery. Intern Med. 2019;58(16):2363–6.
50. Naruse G, Kawasaki M, Yanase K, Tanaka T. Primary angiosarcoma in the right atrium diagnosed by a cardiac tumor biopsy using intracardiac echocardiography. J Med Ultrason. 2020;28(2):120–2.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.